Amplifon S.p.A. stock (IT0004056880): Hearing care leader reports steady growth

Amplifon S.p.A. maintains its position as a leading provider of hearing care services worldwide. The company operates over 5,000 stores across 26 countries, focusing on diagnosis, selection, and personalized fitting of hearing aids. This model drives recurring revenue through aftercare services, appealing to US investors seeking exposure to the aging population trend in Europe and beyond.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Amplifon S.p.A.: core business model

Amplifon S.p.A. specializes in integrated hearing care, combining retail clinics with advanced audiology technology. The company serves private-pay customers and partners with health insurers, generating revenue from device sales (about 40%) and long-term services (60%). Its franchise model amplifies reach without heavy capex, supporting scalability in fragmented markets. For US investors, Amplifon's exposure to Medicare-like systems in Europe offers a proxy for demographic-driven healthcare demand.

The business emphasizes digital tools like tele-audiology and AI-driven fitting, enhancing customer retention. Amplifon reported network growth to 5,300 points of sale as of its latest annual filing covering 2024, published in March 2025 per company IR as of 03/2025.

Main revenue and product drivers for Amplifon S.p.A.

Hearing aid sales remain the top driver, fueled by premium devices from partners like Phonak and Widex. Services such as maintenance and adjustments contribute steady cash flow, with margins around 25% in recent periods. Geographic expansion into the US via acquisitions bolsters growth, with North America now 15% of revenue per 2024 report published March 2025.

Amplifon benefits from aging demographics: over 1.5 billion people globally face hearing loss, per WHO data cited in company filings. US investors note parallels to domestic players like Sonova, with Amplifon's lower valuation offering value in the sector.

Industry trends and competitive position

The hearing care market grows at 6-8% CAGR through 2030, driven by OTC devices and telehealth, per sector reports. Amplifon holds 10% share in Europe, competing with Sonova and Demant. Its service-led model differentiates from pure device makers, capturing higher lifetime value per patient.

Recent trends include AI integration for better outcomes, where Amplifon invests via R&D at 3% of sales. For US portfolios, the company's 20% US revenue exposure ties it to domestic aging trends.

Why Amplifon S.p.A. matters for US investors

Listed on Borsa Italiana, Amplifon trades as ADR-eligible shares, accessible via US brokers. Its 12% revenue from North America links performance to US healthcare spending, which hit $4.5 trillion in 2024. Investors tracking EU healthcare gain diversification with demographic tailwinds mirroring the US.

Conclusion

Amplifon S.p.A. stands out in hearing care with a scalable clinic network and service focus. Steady demographics support long-term demand, while digital innovations position it competitively. US investors may track its North American push and valuation versus peers for portfolio context.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.